376 related articles for article (PubMed ID: 19009291)
21. Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity.
Cho JS; Hsu JV; Morrison SL
Cancer Immunol Immunother; 2009 Jul; 58(7):1057-69. PubMed ID: 19018533
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
Lozano T; Villanueva L; Durántez M; Gorraiz M; Ruiz M; Belsúe V; Riezu-Boj JI; Hervás-Stubbs S; Oyarzábal J; Bandukwala H; Lourenço AR; Coffer PJ; Sarobe P; Prieto J; Casares N; Lasarte JJ
J Immunol; 2015 Oct; 195(7):3180-9. PubMed ID: 26324768
[TBL] [Abstract][Full Text] [Related]
23. Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance.
Lee KJ; Moon JY; Choi HK; Kim HO; Hur GY; Jung KH; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Yoo SH; Kang KH; Lee SY
Clin Exp Immunol; 2010 Aug; 161(2):298-305. PubMed ID: 20491794
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 binding to CD4 on CD4+CD25+ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of immunosuppression.
Ji J; Cloyd MW
Int Immunol; 2009 Mar; 21(3):283-94. PubMed ID: 19208751
[TBL] [Abstract][Full Text] [Related]
25. Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF-β pathway.
Grainger JR; Smith KA; Hewitson JP; McSorley HJ; Harcus Y; Filbey KJ; Finney CA; Greenwood EJ; Knox DP; Wilson MS; Belkaid Y; Rudensky AY; Maizels RM
J Exp Med; 2010 Oct; 207(11):2331-41. PubMed ID: 20876311
[TBL] [Abstract][Full Text] [Related]
26. HSP70 enhances immunosuppressive function of CD4(+)CD25(+)FoxP3(+) T regulatory cells and cytotoxicity in CD4(+)CD25(-) T cells.
Wachstein J; Tischer S; Figueiredo C; Limbourg A; Falk C; Immenschuh S; Blasczyk R; Eiz-Vesper B
PLoS One; 2012; 7(12):e51747. PubMed ID: 23300563
[TBL] [Abstract][Full Text] [Related]
27. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.
Valzasina B; Guiducci C; Dislich H; Killeen N; Weinberg AD; Colombo MP
Blood; 2005 Apr; 105(7):2845-51. PubMed ID: 15591118
[TBL] [Abstract][Full Text] [Related]
28. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
[TBL] [Abstract][Full Text] [Related]
29. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
[TBL] [Abstract][Full Text] [Related]
30. CD8 blockade promotes the expansion of antigen-specific CD4+ FOXP3+ regulatory T cells in vivo.
Wang Z; Davies JD
Int Immunopharmacol; 2007 Feb; 7(2):249-65. PubMed ID: 17178393
[TBL] [Abstract][Full Text] [Related]
31. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells.
Kessel A; Haj T; Peri R; Snir A; Melamed D; Sabo E; Toubi E
Autoimmun Rev; 2012 Jul; 11(9):670-7. PubMed ID: 22155204
[TBL] [Abstract][Full Text] [Related]
32. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.
Coe D; Begom S; Addey C; White M; Dyson J; Chai JG
Cancer Immunol Immunother; 2010 Sep; 59(9):1367-77. PubMed ID: 20480365
[TBL] [Abstract][Full Text] [Related]
33. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
[No Abstract] [Full Text] [Related]
34. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
35. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
[TBL] [Abstract][Full Text] [Related]
36. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
[TBL] [Abstract][Full Text] [Related]
37. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC.
Li L; Chao QG; Ping LZ; Xue C; Xia ZY; Qian D; Shi-ang H
Cancer Biother Radiopharm; 2009 Jun; 24(3):357-67. PubMed ID: 19538059
[TBL] [Abstract][Full Text] [Related]
38. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.
Allan SE; Crome SQ; Crellin NK; Passerini L; Steiner TS; Bacchetta R; Roncarolo MG; Levings MK
Int Immunol; 2007 Apr; 19(4):345-54. PubMed ID: 17329235
[TBL] [Abstract][Full Text] [Related]
39. Lactoferrin Potentiates Inducible Regulatory T Cell Differentiation through TGF-β Receptor III Binding and Activation of Membrane-Bound TGF-β.
Jang YS; Song HE; Seo GY; Jo HJ; Park S; Park HW; Kim TG; Kang SG; Yoon SI; Ko HJ; Lee GS; Park SR; Kim PH
J Immunol; 2021 Nov; 207(10):2456-2464. PubMed ID: 34615735
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide enhances anti-myeloma cellular immunity.
Luptakova K; Rosenblatt J; Glotzbecker B; Mills H; Stroopinsky D; Kufe T; Vasir B; Arnason J; Tzachanis D; Zwicker JI; Joyce RM; Levine JD; Anderson KC; Kufe D; Avigan D
Cancer Immunol Immunother; 2013 Jan; 62(1):39-49. PubMed ID: 22733396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
